Search International and National Patent Collections

1. (WO2017021526) IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS

Pub. No.:    WO/2017/021526    International Application No.:    PCT/EP2016/068726
Publication Date: Fri Feb 10 00:59:59 CET 2017 International Filing Date: Sat Aug 06 01:59:59 CEST 2016
IPC: C07K 16/28
G01N 33/574
A61K 39/395
A61P 35/02
Applicants: AMGEN RESEARCH (MUNICH) GMBH
Inventors: FIEDLER, Walter
WELLBROCK, Jasmin
STAMM, Hauke
KLINGLER, Felix
Title: IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS
Abstract:
The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against CD1 12 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and a CAR T cell. The present invention further provides a pharmaceutical composition comprising an inhibitor against CD1 12 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT and an antibody construct that is capable of engaging T cells.